INTS vs. TIL, ELUT, ABOS, BDTX, CDTX, CADL, FENC, CGEN, CHRS, and CRDF
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Instil Bio (TIL), Elutia (ELUT), Acumen Pharmaceuticals (ABOS), Black Diamond Therapeutics (BDTX), Cidara Therapeutics (CDTX), Candel Therapeutics (CADL), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Coherus BioSciences (CHRS), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.
Intensity Therapeutics, Inc. Common stock vs.
Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
Intensity Therapeutics, Inc. Common stock is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
Instil Bio received 91 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 50.25% of users gave Instil Bio an outperform vote.
3.7% of Intensity Therapeutics, Inc. Common stock shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 18.6% of Intensity Therapeutics, Inc. Common stock shares are held by insiders. Comparatively, 46.5% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Instil Bio's return on equity of -37.44% beat Intensity Therapeutics, Inc. Common stock's return on equity.
In the previous week, Intensity Therapeutics, Inc. Common stock and Intensity Therapeutics, Inc. Common stock both had 5 articles in the media. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Instil Bio's score of -0.28 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the media.
Intensity Therapeutics, Inc. Common stock presently has a consensus target price of $8.50, suggesting a potential upside of 188.14%. Instil Bio has a consensus target price of $145.00, suggesting a potential upside of 521.52%. Given Instil Bio's higher possible upside, analysts clearly believe Instil Bio is more favorable than Intensity Therapeutics, Inc. Common stock.
Intensity Therapeutics, Inc. Common stock has a beta of 4.01, meaning that its share price is 301% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
Summary
Intensity Therapeutics, Inc. Common stock and Instil Bio tied by winning 7 of the 14 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
This page (NASDAQ:INTS) was last updated on 11/21/2024 by MarketBeat.com Staff
Free INTS Stock Alerts